NCT02666612
Unknown
Not Applicable
Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer
ConditionsMetastatic Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastatic Cancer
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Enrollment
- 2240
- Locations
- 1
- Primary Endpoint
- Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry
- Last Updated
- 9 years ago
Overview
Brief Summary
Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with metastatic solid tumor
- •Age\> 18 years
- •Signed consent
Exclusion Criteria
- •Patients with diseases associated with vascular lesions known.
- •Patients protected by law, in accordance with Articles L1121-5 to L1121-8 of the Code of Public Health.
- •Mental pathology that can interfere with the proper conduct of the study.
- •Refusal of consent.
Outcomes
Primary Outcomes
Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry
Time Frame: up to 2 years
Measurement and characterization of initial CEC and CEP circulaing DNA and their evolution under treatment
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerChronic Obstructive Pulmonary DiseaseNCT00826683University Hospital, Limoges140
Completed
Not Applicable
The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHDHypertension,PulmonaryNCT02267200Shanghai Jiao Tong University School of Medicine30
Terminated
Phase 2
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast CancerBreast CancerNCT00845910Hoffmann-La Roche22
Completed
Not Applicable
Studying Blood Samples in Women With Breast Cancer or a History of Breast CancerBreast CancerNCT00898703University of Arizona50
Completed
Not Applicable
Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal GammopathyMonoclonal GammopathyMonoclonal Gammopathy of Undetermined SignificationMyelomaNCT01543100Rennes University Hospital60